Temporal trends of blood eosinophilia in severe uncontrolled CRSwNP treated with dupilumab: a real-life study.
Biological therapy
Blood eosinophilia
Chronic rhinosinusitis with nasal polyps
Dupilumab
Hyper-eosinophilia
Journal
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
ISSN: 1434-4726
Titre abrégé: Eur Arch Otorhinolaryngol
Pays: Germany
ID NLM: 9002937
Informations de publication
Date de publication:
29 Dec 2023
29 Dec 2023
Historique:
received:
15
11
2023
accepted:
11
12
2023
medline:
2
1
2024
pubmed:
2
1
2024
entrez:
29
12
2023
Statut:
aheadofprint
Résumé
Induced eosinophilia is commonly related to dupilumab treatment. We analysed the temporal trends of blood eosinophilia in patients with severe uncontrolled CRSwNP during the first year of treatment with dupilumab in real-life setting to evaluate its correlation with outcomes of response and adverse events (AEs). Seventy-four patients with severe uncontrolled CRSwNP treated with dupilumab at our institution were enrolled. At each visit, we evaluated AEC, outcomes of response to treatment and AEs. A significant increase in AEC was observed since the first month with a peak at 3 months; at 12 months, the values returned comparable to those at baseline. A ≥ 50% increase of the baseline AEC with a value greater than 500 cells/mm In our series, we observed that an increase in AEC with different temporal trends may be observed in CRSwNP patients during the first year of treatment with dupilumab. In our series, eosinophilia is not correlated with a negative outcome of response to treatment or a risk of AEs.
Identifiants
pubmed: 38157036
doi: 10.1007/s00405-023-08417-8
pii: 10.1007/s00405-023-08417-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S (2020) European position paper on rhinosinusitis and nasal polyps 2020. Rhinology 58(Suppl 29):1–464. https://doi.org/10.4193/Rhin20.600
doi: 10.4193/Rhin20.600
pubmed: 32078669
Fokkens WJ, Viskens AS, Backer V, Conti D, De Corso E, Gevaert P et al (2023) EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023. Rhinology 61(3):194–202. https://doi.org/10.4193/Rhin22.489
doi: 10.4193/Rhin22.489
pubmed: 36999780
De Corso E, Bellocchi G, De Benedetto M, Lombardo N, Macchi A, Malvezzi L et al (2022) Biologics for severe uncontrolled chronic rhinosinusitis with nasal polyps: a change management approach. Consensus of the Joint Committee of Italian Society of Otorhinolaryngology on biologics in rhinology. Acta Otorhinolaryngol Ital 42(1):1–16. https://doi.org/10.14639/0392-100X-N1614
doi: 10.14639/0392-100X-N1614
pubmed: 34297014
Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P et al (2016) Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis. JAMA 315(5):469
doi: 10.1001/jama.2015.19330
pubmed: 26836729
Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE et al (2019) Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. The Lancet 394(10209):1638–1650. https://doi.org/10.1001/jama.2015.19330
doi: 10.1001/jama.2015.19330
De Corso E, Settimi S, Montuori C, Corbò M, Passali GC, Porru D et al (2022) Effectiveness of dupilumab in the treatment of patients with severe uncontrolled CRSwNP: a “real-life” observational study in the first year of treatment. JCM 11(10):2684. https://doi.org/10.3390/jcm11102684
doi: 10.3390/jcm11102684
pubmed: 35628815
Cantone E, De Corso E, Ricciardiello F, Di Nola C, Grimaldi G, Allocca V et al (2022) Olfaction recovery following dupilumab is independent of nasal polyp reduction in CRSwNP. JPM 12(8):1215. https://doi.org/10.3390/jpm12081215
doi: 10.3390/jpm12081215
pubmed: 35893310
Otten J, van der Lans R, De Corso E, Dziadziulia K, Hilvering B, Weersink E et al (2023) Evaluation of switching or simultaneous use of biologic treatment in patients with severe chronic rhinosinusitis with nasal polyps and severe asthma. Considerations in clinical decision making. Expert Rev Clin Immunol 29:1–9. https://doi.org/10.1080/1744666X.2023.2218617
doi: 10.1080/1744666X.2023.2218617
van der Lans RJL, Fokkens WJ, Adriaensen GFJPM, Hoven DR, Drubbel JJ, Reitsma S (2022) Real-life observational cohort verifies high efficacy of dupilumab for chronic rhinosinusitis with nasal polyps. Allergy 77(2):670–674. https://doi.org/10.1111/all.15134
doi: 10.1111/all.15134
pubmed: 34626497
De Corso E, Pipolo C, Cantone E, Ottaviano G, Gallo S, Trimarchi M et al (2023) Practical recommendations for managing severe chronic rhinosinusitis with nasal polyps in the era of biologics. Acta Otorhinolaryngol Ital. https://doi.org/10.14639/0392-100X-N2422
doi: 10.14639/0392-100X-N2422
pubmed: 37698095
De Corso E, Pasquini E, Trimarchi M, La Mantia I, Pagella F, Ottaviano G et al (2023) Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): a multicentric observational phase IV real-life study (DUPIREAL). Allergy. https://doi.org/10.1111/all.15772
doi: 10.1111/all.15772
pubmed: 38108602
Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF et al (2018) Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 378(26):2486–2496. https://doi.org/10.1056/NEJMoa1804092
doi: 10.1056/NEJMoa1804092
pubmed: 29782217
Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L et al (2018) Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 378(26):2475–2485. https://doi.org/10.1056/NEJMoa1804093
doi: 10.1056/NEJMoa1804093
pubmed: 29782224
Thaçi D, Simpson EL, Beck LA et al (2016) Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet 387(10013):40–52. https://doi.org/10.1016/S0140-6736(15)00388-8
doi: 10.1016/S0140-6736(15)00388-8
pubmed: 26454361
Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D et al (2017) Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 389(10086):2287–2303
doi: 10.1016/S0140-6736(17)31191-1
pubmed: 28478972
Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ et al (2016) Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 375(24):2335–2348. https://doi.org/10.1016/S0140-6736(17)31191-1
doi: 10.1016/S0140-6736(17)31191-1
pubmed: 27690741
Wechsler ME, Ford LB, Maspero JF, Pavord ID, Papi A, Bourdin A et al (2022) Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med 10(1):11–25. https://doi.org/10.1016/S2213-2600(21)00322-2
doi: 10.1016/S2213-2600(21)00322-2
pubmed: 34597534
Wechsler ME, Klion AD, Paggiaro P, Nair P, Staumont-Salle D, Radwan A et al (2022) Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis. J Allergy Clin Immunol Pract 10(10):2695–2709. https://doi.org/10.1016/j.jaip.2022.05.019
doi: 10.1016/j.jaip.2022.05.019
pubmed: 35636689
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP et al (2014) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg 12(12):1495–1499. https://doi.org/10.1016/j.ijsu.2014.07.013
doi: 10.1016/j.ijsu.2014.07.013
Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W et al (2013) Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol 131(1):110–6.e1. https://doi.org/10.1016/j.jaci.2012.07.047
doi: 10.1016/j.jaci.2012.07.047
pubmed: 23021878
Linder A (1988) Symptom scores as measures of the severity of rhinitis. Clin Allergy 18(1):29–37. https://doi.org/10.1111/j.1365-2222.1988.tb02840.x
doi: 10.1111/j.1365-2222.1988.tb02840.x
pubmed: 3349590
Gallo S, Russo F, Mozzanica F, Preti A, Bandi F, Costantino C et al (2020) Prognostic value of the Sinonasal Outcome Test 22 (SNOT-22) in chronic rhinosinusitis. Acta Otorhinolaryngol Ital 40(2):113–121. https://doi.org/10.14639/0392-100X-N0364
doi: 10.14639/0392-100X-N0364
pubmed: 32469005
Scadding G, Hellings P, Alobid I, Bachert C, Fokkens W, van Wijk RG et al (2011) Diagnostic tools in Rhinology EAACI position paper. Clin Transl Allergy 1(1):2. https://doi.org/10.1186/2045-7022-1-2
doi: 10.1186/2045-7022-1-2
pubmed: 22410181
Hummel T, Kobal G, Gudziol H, Mackay-Sim A (2007) Normative data for the “Sniffin’ Sticks” including tests of odor identification, odor discrimination, and olfactory thresholds: an upgrade based on a group of more than 3,000 subjects. Eur Arch Otorhinolaryngol 264(3):237–243. https://doi.org/10.1007/s00405-006-0173-0
doi: 10.1007/s00405-006-0173-0
pubmed: 17021776
Kuang FL (2020) Approach to patients with eosinophilia. Med Clin North Am 104(1):1–14. https://doi.org/10.1016/j.mcna.2019.08.005
doi: 10.1016/j.mcna.2019.08.005
pubmed: 31757229
Hilderink JM, Klinkenberg LJJ, Aakre KM, de Wit NCJ, Henskens YMC, van der Linden N et al (2017) Within-day biological variation and hour-to-hour reference change values for hematological parameters. Clin Chem Lab Med 55(7):1013–1024. https://doi.org/10.1515/cclm-2016-0716
doi: 10.1515/cclm-2016-0716
pubmed: 28002028
Caminati M, Olivieri B, Dama A, Micheletto C, Paggiaro P, Pinter P et al (2022) Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management. Expert Rev Respir Med 16(7):713–721. https://doi.org/10.1080/17476348.2022.2090342
doi: 10.1080/17476348.2022.2090342
pubmed: 35703018
Chen YY, Khoury P, Ware JM, Holland-Thomas NC, Stoddard JL, Gurprasad S et al (2014) Marked and persistent eosinophilia in the absence of clinical manifestations. J Allergy Clin Immunol 133(4):1195–1202. https://doi.org/10.1016/j.jaci.2013.06.037
doi: 10.1016/j.jaci.2013.06.037
pubmed: 23987798
Helbig G, Hus M, Francuz T, Dziaczkowska-Suszek J, Soja A, Kyrcz-Krzemień S (2014) Characteristics and clinical outcome of patients with hypereosinophilia of undetermined significance. Med Oncol 31(1):815. https://doi.org/10.1007/s12032-013-0815-1
doi: 10.1007/s12032-013-0815-1
pubmed: 24338273
Bjerrum OW, Siersma V, Hasselbalch HC, Lind B, Andersen CL (2019) Association of the blood eosinophil count with end-organ symptoms. Ann Med Surg (Lond) 9(45):11–18. https://doi.org/10.1016/j.amsu.2019.06.015
doi: 10.1016/j.amsu.2019.06.015
Campisi R, Crimi C, Nolasco S, Beghè B, Antonicelli L, Guarnieri G et al (2021) Real-world experience with dupilumab in severe asthma: one-year data from an italian named patient program. J Asthma Allergy 14:575–583. https://doi.org/10.2147/JAA.S312123
doi: 10.2147/JAA.S312123
pubmed: 34079295
Dupin C, Belhadi D, Guilleminault L, Gamez AS, Berger P, De Blay F et al (2020) Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort. Clin Exp Allergy 50(7):789–798. https://doi.org/10.1111/cea.13614
doi: 10.1111/cea.13614
pubmed: 32469092
Renner A, Marth K, Patocka K, Idzko M, Pohl W (2021) Dupilumab rapidly improves asthma control in predominantly anti-IL5/IL5R pretreated Austrian real-life severe asthmatics. Immun Inflamm Dis 9(3):624–627. https://doi.org/10.1002/iid3.434
doi: 10.1002/iid3.434
pubmed: 33960689
Ferrucci S, Casazza G, Angileri L, Tavecchio S, Germiniasi F, Berti E et al (2020) Clinical response and quality of life in patients with severe atopic dermatitis treated with dupilumab: a single-center real-life experience. J Clin Med 9(3):791. https://doi.org/10.3390/jcm9030791
doi: 10.3390/jcm9030791
pubmed: 32183179
Marcant P, Balayé P, Merhi R, Jendoubi F, Nosbaum A, Raison-Peyron N et al (2021) Dupilumab-associated hypereosinophilia in patients treated for moderate-to-severe atopic dermatitis. J Eur Acad Dermatol Venereol 35(6):e394–e396. https://doi.org/10.1111/jdv.17177
doi: 10.1111/jdv.17177
pubmed: 33594731
Patruno C, Napolitano M, Argenziano G, Peris K, Ortoncelli M, Girolomoni G et al (2021) Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study. J Eur Acad Dermatol Venereol 35(4):958–964. https://doi.org/10.1111/jdv.17094
doi: 10.1111/jdv.17094
pubmed: 33332697
Fargnoli MC, Esposito M, Ferrucci S, Girolomoni G, Offidani A, Patrizi A et al (2021) Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis. J Dermatolog Treat 32(5):507–513. https://doi.org/10.1080/09546634.2019.1682503
doi: 10.1080/09546634.2019.1682503
pubmed: 31647347
Ahn J, Bae JY, Seo SJ (2020) A retrospective case series hypereosinophilia during dupilumab treatment: hypereosinophilia could be a pharmacogenetic biomarker of dupilumab. Dermatol Ther 33(6):e13847. https://doi.org/10.1111/dth.13847
doi: 10.1111/dth.13847
pubmed: 32544266
Loperfido A, Ciofalo A, Cavaliere C, Begvarfaj E, Cascone F, Alfonzo G et al (2023) Dupilumab’s impact on blood parameters in nasal polyposis: 18-month follow-up in real life. J Immunol Res 2023:4027701. https://doi.org/10.1155/2023/4027701
doi: 10.1155/2023/4027701
pubmed: 37745203
Rampi A, Tanzini U, Vinciguerra A, Danè G, Moroni L, Yacoub MR et al (2023) Early increase in eosinophil count may predict long-term hypereosinophilia during dupilumab treatment: a 2-year observational study. Int Forum Allergy Rhinol. https://doi.org/10.1002/alr.23212
doi: 10.1002/alr.23212
pubmed: 37316962
Kemp P, van der Lans RJL, Otten JJ, Adriaensen GFJPM, Benoist LBL, Cornet ME, Hoven DR, Rinia B, Verkest V, Fokkens WJ, Reitsma S (2023) Hypereosinophilia during dupilumab treatment in patients with chronic rhinosinusitis with nasal polyps. Rhinology. https://doi.org/10.4193/Rhin23.357
doi: 10.4193/Rhin23.357
pubmed: 37999634
Wollenberg A, Beck LA, Blauvelt A, Simpson EL, Chen Z, Chen Q et al (2020) Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). Br J Dermatol 182(5):1120–1135. https://doi.org/10.1111/bjd.18434
doi: 10.1111/bjd.18434
pubmed: 31407311
Ryser FS, Yalamanoglu A, Valaperti A, Brühlmann C, Mauthe T, Traidl S et al (2023) Dupilumab-induced eosinophilia in patients with diffuse type 2 chronic rhinosinusitis. Allergy 78(10):2712–2723. https://doi.org/10.1111/all.15844
doi: 10.1111/all.15844
pubmed: 37548395
Lommatzsch M, Stoll P, Winkler J, Zeise-Wehry D, Tronnier M, Weber MA et al (2021) Eosinophilic pleural effusion and stroke with cutaneous vasculitis: two cases of dupilumab-induced hypereosinophilia. Allergy 76(9):2920–2923. https://doi.org/10.1111/all.14964
doi: 10.1111/all.14964
pubmed: 34047387
Briegel I, Felicio-Briegel A, Mertsch P, Kneidinger N, Haubner F, Milger K (2021) Hypereosinophilia with systemic manifestations under dupilumab and possibility of dual benralizumab and dupilumab therapy in patients with asthma and CRSwNP. J Allergy Clin Immunol Pract 9(12):4477–4479. https://doi.org/10.1016/j.jaip.2021.07.049
doi: 10.1016/j.jaip.2021.07.049
pubmed: 34384930
Kimura A, Takeda A, Ikebukuro T, Hori J (2021) Serum IgE reduction and paradoxical eosinophilia associated with allergic conjunctivitis after dupilumab therapy. J Ophthalmic Inflamm Infect 11(1):3. https://doi.org/10.1186/s12348-020-00234-y
doi: 10.1186/s12348-020-00234-y
pubmed: 33586015